1606 Corp. target Adnexus merges with Sanctum for HIV and COVID-19 assets

1606 CORP.

Adnexus Biotechnologies completed acquisition of Sanctum Therapeutics' core tech assets for HIV and SARS-CoV-2.
Combines Adnexus AI drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and monoclonal antibodies.
1606 Corp. has a letter of intent for a 5% equity stake in Adnexus; LOI expires November 27, 2024.
CEO Austen Lambrecht calls merger a pivotal moment in fighting infectious diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.